CNBC's Angelica Peebles reports on themes emerging in the pharma space.
BreakdownGenerated by LeadStory AI
- Merck is buying Verona Pharma for about $10 billion to diversify beyond Keytruda. 5s
- Keytruda's patent expiration is expected to create a $30 billion revenue gap for Merck. 26s
- Verona's COPD drug is already on the market, with $70 million in first-quarter sales. 55s
- The acquisition aligns with a trend of pharma companies buying commercial-stage firms. 1m 0s
- Verona's drug may have further sales potential through additional indications. 1m 29s